Bioinformatics Analysis Identifies EPAS1 as a Novel Prognostic Marker Correlated with Immune Infiltration in Acute Myeloid Leukemia

Table 4

EPAS1 expression associated with clinicopathologic characteristics (logistic regression).

Characteristics	Total ()	Odds ratio (OR)	value
WBC count (×10^9/L) (>20 vs. <=20)	150	0.42 (0.22-0.80)	0.009
PB blasts (%) (>70 vs. <=70)	151	0.46 (0.24-0.88)	0.019
BM blasts (%) (>20 vs. <=20)	151	0.31 (0.16-0.61)	<0.001
Cytogenetic risk (poor vs. favorable & intermediate)	149	1.58 (0.75-3.43)	0.234
FLT3 mutation (positive vs. negative)	147	0.41 (0.19-0.84)	0.017
IDH1 R132 mutation (positive vs. negative)	149	0.42 (0.11-1.35)	0.164
IDH1 R140 mutation (positive vs. negative)	149	0.49 (0.13-1.64)	0.266
RAS mutation (positive vs. negative)	150	0.32 (0.05-1.46)	0.176
NPM1 mutation (positive vs. negative)	150	0.20 (0.08-0.48)	<0.001
DNMT3A mutation (positive vs. negative)	109	1.70 (0.60-5.05)	0.321
RUNX1 mutation (positive vs. negative)	109	1.62 (0.48-5.80)	0.438

PB: peripheral blood; BM: bone marrow. statistically significant, .